Centricity Vision

Executive Summary

Centricity Vision is a private, commercial-stage ophthalmic medical device company headquartered in Irvine, California. The company specializes in developing and commercializing technologies for cataract and refractive surgery, with a core focus on enhancing surgical precision and efficiency. Its flagship product, the ZEPTOLink IOL Positioning System, uniquely integrates capsulotomy technology with standard phacoemulsification systems, aiming to improve intraocular lens (IOL) positioning and surgical outcomes. Cataract surgery is one of the most common procedures globally, driven by an aging population, and the market increasingly demands technologies that reduce complications and improve refractive accuracy. Centricity's solution addresses a key pain point in IOL alignment, which is critical for post-operative visual outcomes. While the company faces competition from established players like Alcon, Johnson & Johnson, and Bausch + Lomb, its differentiated approach could carve a niche in the precision surgery segment. As a private entity, Centricity has limited public financial disclosures, but its innovative platform positions it for potential growth through clinical adoption and strategic partnerships. The success of ZEPTOLink hinges on real-world evidence demonstrating improved efficiency and patient outcomes compared to current standards. Looking ahead, Centricity Vision's trajectory will depend on expanding commercial traction in U.S. and international markets, as well as securing additional clinical validation. The company may also pursue broader indications or next-generation enhancements to its system. Given the competitive landscape and capital requirements for scaling a med-tech business, near-term catalysts are likely centered on key account wins, regulatory clearances in new geographies, and data releases. While the company has not disclosed recent funding or specific milestones, its proprietary technology and early commercial presence warrant moderate conviction. The next 12–18 months will be critical for demonstrating market acceptance and building a pathway to profitability.

Upcoming Catalysts (preview)

• Q4 2026First major hospital system contract for ZEPTOLink in U.S.60% success
• Q4 2026Publication of pivotal clinical study results demonstrating superiority in IOL positioning accuracy50% success
• Q1 2027Strategic partnership with a leading ophthalmic surgical equipment distributor for international expansion45% success